GLOMERULONEPHRITIS Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Heavy Proteinuria Low serum Albumin Edema High serum lipids Nephritis Renal failure Hypertension Hematuria Acute Chronic Rapidly Progressive Asymptomatic Urinary Abnormalities 1
Urine Analysis Urinary RBC s, sometimes deformed RBC Casts Large amounts Albuminuria ( >3g/Day ) 2
3
Approach to Glomerulonephritis 1. Morphologic 2. Immunologic 3. Etiologic 4. Clinical Vulnerability of Glomerulus to IC Injury 1. 20-25% 2 of cardiac output 2. High glomerular capillary pressure 3. Fenestrated endothelium 4. Concentration (sieving effect) 4
Mechanisms of Immunologic Injury to the Glomerulus 1. Glomerular l deposition i of circulating i Ag-Ab complexes 2. Binding of Circulating Ab to fixed glomerular Ag (i.e. anti-gbm Ab) 3. In situ immune complex formation 5
Glomerular Proliferation 1. Endocapillary 2 Extracapillary 2. Extracapillary (crescentic) 6
Patterns of Glomerular Disease: Proliferation or Sclerosis 1. Focal Vs Diffuse 2. Segmental Vs Global Approach to Glomerular Disease: Etiology History Physical Exam Laboratory, Radiological tests s Primary Glomerular Disease e.g. minimal change disease Secondary (Systemic) Disease e.g. Lupus 7
7 year old child Several days of sore throat + low grade fever; he is given acetaminophen, and recovers uneventfully. 2 wks later develops dark, coca-cola colored urine and notes urinating less. Exam: pedal edema and elevated blood pressure. Labs: Urine: rbc s, rbc casts, 2+ prot. Creatinine 2.4 mg/dl 8
Acute Nephritic Syndrome Decreased GFR Oliguria Edema Hypertension Active urine sediment 9
10
11
12
13
14
15
16
17
18
19
20
21
Etiology: Post-streptococcal GN Following infection with certain nephritogenic streptococcal strains (pharyngitic, dermal, etc) Children more common than adults Time lag from infection to onset of GN Nephritic picture common Low complement and C3 Positive serologic tests for recent strep infection Prognosis: excellent in children; good in adults Serum Complement Levels in Glomerulonephritis Low Levels acute post-infectious GN lupus nephritis idiopathic MPGN cryoglobulinemic GN Normal Levels IgA nephropathy p ANCA-RPGN / Wegener s / Microscopic PAN Anti-GBM disease Minimal change, FSGS, Membranous, Diabetes, Amyloid, etc. 22
A 16 year old high school junior notices dark brown urine after playing basketball. Labs: Creatinine 1.1 mg/dl Urinary sediment has rbc s and rbc casts. Creatinine clearance 128 cc/min 660 mg proteinuria/day Serologic tests are normal or negative 23
24
Demographics of IgA Nephropathy Ages 4 80 (mean 25) years (65% of patients in 2 nd /3 rd decade) M/F = 2/1 Rare in blacks Incidence (% primary glomerulopathies) 5-10% N. America U.K. Scandinavia 20-30% Europe Australia 25-45% Asia 25
Pathogenesis 1. Defective hepatic clearance Liver cirrhosis 2. Increased IgA production Association with elevated serum IgA Onset may follow URI or Gastroenteritis 3. Defect of antigen exclusion at the mucosal surface URI Gastroenteritis Celiac disease 26
Structure of Human Secretory IgA (siga) Henoch-Schönlein Purpura 27
Henoch-Schönlein Purpura Vasculitis with IgA-dominant immune deposits affecting small vessels, i.e. capillaries, venules, or arterioles. Typically involves skin, gut & glomeruli, and is associated with arthralgias or arthritis. Henoch-Schönlein Purpura Schönlein-Henoch Purpura Purpura Abdominal pain Arthralgias (Nephritis) Edward Henoch Johann Lukas Schönlein 28
Etiology: IgA Nephropathy Most common idiopathic GN worldwide Defined by IgA deposition in mesangium Clinical Presentation Young gross hematuria Adults Proteinuria + hematuria Not benign hematuria ( Berger s Disease ) 20-30 % progress ESRD over 20 years Treatment Options ACE inhibitor/ar blockers Steroids Fish Oil Mycophenolate 29
A 29 year old saleswoman develops arthritis of multiple joints, fever Exam: Lymphadenopathy, and a malar rash. Labs: Urinalysis 3+ protein, 18-20 rbc s Creatinine 1.2 mg/dl 24 hr. protein 1.8 Complement 18% (normal 50-150%) ANA positive, Anti-DNA antibody positive 30
31
32
Lupus Nephritis Class IV 33
Lupus Nephritis WHO Classification CLASSES I Minimal mesangial II Mesangial Proliferative III Focal Proliferative (<50% glom) IV Diffuse Proliferative (> 50% glom) V Membranous VI Chronic sclerosing 34
Lupus Nephritis Class II Class II: Mesangial electron dense deposits 35
Class III: Focal segmental lupus nephritis Class V: Membranous lupus nephritis with spikes 36
Treatment Approach to SLE Nephritis Class I: Minimal mesangial LN(normal ( LM, +deposits) TREAT EXTRARENAL LUPUS Class II: Mesangial proliferative LN TREAT EXTRARENAL LUPUS Class III: Focal LN (<50% of all glomeruli) STEROIDS, CYTOTOXICS Class IV: Diffuse LN (>50% of all glomeruli) STEROIDS, CYTOTOXICS Class V: Membranous LN STEROIDS, CYTOTOXICS (IN HIGH RISK PTS) Class VI: Advanced sclerotic LN (90% sclerosed, no activity) PREPARE FOR RENAL REPLACEMENT Kidney Int. 2004 Feb;65(2):521-30. Probability of Developing End-Stage Renal Disease with Different Treatment Regimens Probability of End-Stage Renal Disease 0 20 40 60 80 IV CYC Oral CYC + AZA Oral CYC AZA Prednisone 100 0 20 40 60 80 100 120 140 160 180 200 220 Months CYC = cyclophosphamide; AZA = azathioprine. Steinberg AD, Steinberg SC. Arthritis Rheum. 1991;34:945-950. 37
Corticosteroids: Side Effects 38
Cyclophosphamide: Side effects EVENT CYCLOPHOSPHAMIDE COMBINATION MAJOR INFECTIONS 50% 50% HERPES ZOSTER 29% 25% HYPERLIPIDEMIA 25% 42% AVASCULAR NECROSIS 29% 30% OSTEOPOROSIS 22% 16% PREMATURE MENOPAUSE 56% 55% Gourley MF.. Ann Int Med 135: 248-247, 2001 Strategies for Alternate Therapies Sequential cytotoxic therapy Cyclophosphamide followed by Mycophenolate/Imuran Mycophenolate 39
A 58 year old insurance salesman develops sinusitis, weight loss, malaise and a dry cough over three weeks. His sinus films show opacification of the left maxillary sinus, and he is found to have a cavitary lesion on his chest X-ray. Labs: Urinalysis: rbc s, wbc s, and rbc casts Creatinine 2.7 mg/dl Serum complement is normal Anti-GBM antibodies are absent ANCA is positive 40
41
42
43
44
45
Pulmonary-Renal Vasculitic Syndrome Pauci-immune i (usually ANCA associated) Wegener s granulomatosis Microscopic Polyangiitis Immune Complex Deposits (granular) SLE Cryoglobulinemic vasculitis Anti-Glomerular Basement Membrane Antibody Deposits (linear) Goodpasture s Syndrome 46
ANTIBODY MEDIATED GLOMERULONEPHRITIS Circulating anti-gbm Glomerular immune Circulating ANCA with antibodies with linear complex localization with paucity of glomerular IF glomerular IF staining granular IF staining immunoglobulin staining >80% ANCA+ 47
48
49
50
51
Rapidly Progressive Glomerulonephritis Rapidly progressive renal failure (weeks) RPGN = Crescentic GN Pathogenesis Anti-GBM disease Immune complex GN Pauci-immune immune GN Treatment and Course depend on etiology and stage 52
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) Anti proteinase-3 (PR3) Anti- myeloperoxidase (MPO) ANCA is to RPGN as Anti-DNA is to SLE 53